List of SELECT Publications
SELECT Data and Safety Monitoring Committee (DSMC) met in September 2008 to
review the data to date. Thanks to each and every participant, enough data were
available to make a decision about the effectiveness of the Study Supplements.
The data showed that 200 mg of selenium and 400 IUs daily of vitamin E do not
prevent prostate cancer. Investigators from the study leadership and the
National Cancer Institute agreed with the DSMCís findings. Participants in
SELECT should stop taking their Study Supplements.
not over. There is valuable information to be gained by continuing participant
follow-up. The data to date suggest, but do not prove, that vitamin E may
slightly increase the chance of getting prostate cancer, and that selenium may
increase the chance of getting diabetes mellitus. We emphasize that these
findings are not proven. We will learn more about the effects of the Study
Supplements as we continue to monitor our participantsí health. Participant
safety is our priority.
site staff will gather information on participantsí current health and medical
information at study site visits. As one of the largest medical studies of men,
SELECT will help answer many critical questions about menís health and will
assist scientists in the future.
Participants will receive a letter about this transition from the study
leadership. The letter will be mailed to them by their local study site.
Continue to check this website for periodic updates. If you are a participant in
SELECT, you can contact your Study Site for more information.
Contact information for your Study
Site can be found in the
list of SELECT Study Sites.
to all the participants on SELECT, we now know that selenium and vitamin E do
not prevent prostate cancer. This important public health message is a result of
over 35,000 men participating in SELECT. The SELECT National Participant
Advisory Board and the leadership of SELECT appreciate each participantís
commitment. The best way for participants to maximize their contribution is to
continue to participate in SELECT.
Frequently Asked Questions and Responses
1. Why did SELECT get
these results, when previous studies suggested that selenium and vitamin
E are helpful?
incidence, or rate of occurrence, of prostate cancer in the other
studies was not the primary focus or endpoint. Men in those studies were
not screened with the blood test of PSA (prostate specific antigen) and
DRE (digital rectal exam) regularly. SELECT is the only study where the
question of whether either selenium or vitamin E would prevent prostate
cancer was asked directly and where prostate cancer was the primary
2. Should you avoid taking a multivitamin that contains either or both
of these supplements?
Answer: No, as long as you take only one multivitamin a day.
3. Since vitamin E
and selenium donít work, is there anything else you can do to help
reduce your risk of prostate cancer?
Prostate Cancer Prevention Trial (PCPT) showed that taking the drug
finasteride reduces the risk of prostate cancer by 25%. You should
discuss with your doctor whether it makes sense for you to take
finasteride. Finasteride may also be prescribed for men with lower
urinary tract symptoms due to prostate enlargement (BPH).
4. Why do we still want to collect data from SELECT participants if we
already know the results?
Answer: These supplements, selenium and vitamin E, may have
biologic effects even after you stop taking them. We want to continue to
collect data to learn of any long-term effects of these supplements on
the risk of prostate cancer and other diseases including cardiovascular
disease and other cancers.
5. Is there any value
or harm if you eat foods high in selenium or vitamin E?
Answer: There are no proven benefits or harms if you eat foods
high in selenium or vitamin E.
The Selenium and Vitamin E Cancer Prevention Trial (SELECT) is a research
study to determine if selenium and vitamin E can help prevent prostate cancer.
SELECT is funded by the National Cancer Institute and coordinated by the
Southwest Oncology Group. Over 35,000 men, from a variety of ethnic groups,
including 14% African American, 5% Hispanic, 1% Hispanic African American, and
1% Asian, from over 400 Study Sites in the United States, Puerto Rico, and
Canada are participating in SELECT.
more information about prostate cancer?
To find out more about prostate cancer risk factors, prevention, screening,
diagnosis, treatment, or clinical trials, please click on the links provided or
contact the National Cancer Institute's Cancer Information Service at
1-800-4-Cancer (1-800-422-6237) or TTY: 1-800-332-8615. In Canada, call the
Canadian Cancer Societyís Cancer Information Service at 1-888-939-3333.